May 5, 2018 | New York, NY
During the packed session, “Immunotherapies in Schizophrenia and Bipolar Disorder” at the 2018 American Psychiatric Association (APA) Annual Meeting, Dr. Mark Weiser discussed the latest therapies being investigated to treat inflammation in schizophrenia and bipolar disorder. Dr. Mark Weiser is the Associate Director of Treatment Trials at the Stanley Medical Research Institute, a non-profit organization which supports research in schizophrenia and bipolar disorder. This presentation discussed different compounds such as antibiotics (minocycline), antivirals, NSAIDS (asprin) and anti-oxidants. Clinical trials for these compounds showed both positive and negative results, suggestion the need for additional research on this topic. Showing promise were trials for monoclonal antibodies to treat inflammation.
Dr. Weiser also described ongoing studies funded by the Stanley Medical Research Institute and elsewhere on monoclonal antibodies, prednisone and other compounds.
>> Presented at the 2018 American Psychiatric Association (APA) Annual Meeting
For more on inflammation: